Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04389840 · ClinicalTrials.gov registry record · Phase 2
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT04389840 is a Phase 2 study that was terminated before completion, run by Jazz Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT04389840, a Phase 2 study, was terminated before completion, sponsored by Jazz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium in adult patients with acute lung injury (ALI) due to Coronavirus Disease 2019 (COVID-19). This study was designed to determine if dociparstat sodium could accelerate recovery and prevent progression to mechanical ventilation in patients severely affected by COVID-19.
Interventions
- DRUG Placebo
- DRUG Dociparstat sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-07-08 |
| Est. Completion | 2021-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04389840
The ClinicalTrials.gov registry entry for NCT04389840 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04389840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04389840 about?
NCT04389840 is a clinical study titled "Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure". This was a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium in adult patients with acute lung injury (ALI) due to Coronavirus Disease 2019 (COVID-19). This study was designed to determine if dociparstat sodium could accelerate rec...
What is the current status of trial NCT04389840?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2020-07-08. Estimated completion is 2021-05-20.
What interventions are being tested in trial NCT04389840?
The interventions under investigation include: Placebo (DRUG), Dociparstat sodium (DRUG).
Who is sponsoring clinical trial NCT04389840?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.